In addition to above controversy, MSI2 predicts unfavorable outcome in AML and hepatocellular cancer [7, 9, 23, 26], whereas Numb is a better prognostic markers in breast cancer and salivary gland carcinomas [21, 22, 27]. Here, MSI2 is linked to breast carcinoma.